Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer


Background: To evaluate the efficacy and safety of albumin-bound paclitaxel-based chemotherapy in treatmentfor patients with advanced esophageal cancer who failed in first-line chemotherapy. Materials and
Methods: Wecollected29 advanced esophageal cancer patients who received albumin-bound paclitaxel-based chemotherapyfromJune 2009 to September 2013, and the efficacy and safety of the compound were evaluated. These patientswere treated with 100-150mg/m2 nab-paclitaxel on days 1,8.The cycle was repeated every 3 weeks. Clinicalefficacy was evaluated every two cycles.
Results: Of the 29 patients, two persons interrupted treatment because ofadverse reactions, failed to evaluate efficacy effect. The rest of27 patients who could be evaluated for short-termresponse, 10 patients (37%) achieved partial response, 2 (7.4%) remained stable disease, and 15 (55.6%) hadprogressivedisease. The objective response rate was 37%, and the disease control rate was 44.4%.The mediantime to progression was 6.6 months.The major adverse reactions includedalopecia (62.07%), neutropenia (65.5%),gastrointestinalreaction (10.3%) andsensory neuropathy(6.8%).
Conclusions: The albumin-bound paclitaxelbasedchemotherapy is efficacy and safety in treatment for patients with advanced esophageal cancer who failedin first-line chemotherapy.